Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.
|Podcasts|July 1, 2021
OncView™ Podcast: Front-Line Management of Extensive-Stage SCLC
Author(s)Matthew Fowler
This special edition of the “Oncology Peer Review On-The-Go” podcast hosts Mark Socinski, MD, who discusses important factors in treating and managing extensive-stage small cell lung cancer, and details information from the IMpower133 trial.
Advertisement
As part of the OncView™ video series, CancerNetwork® spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida, about updates in the management of extensive-stage small cell lung cancer (ES-SCLC).
In the video series, Socinski discussed the following:
Epidemiology and Clinical Course of SCLC Evolution of Therapies for SCLC Treatment Challenges in Extensive-Stage SCLC Immunotherapy as First-Line Treatment for Extensive-Stage SCLC The IMpower133 Trial in Extensive-Stage SCLC Extensive-Stage SCLC: Implications of IMpower133
To watch more videos in CancerNetwork®’s OncView™ series, visit
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.
Advertisement
Related to this article
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Ursula A. Matulonis, MD, surveyed the exploitable genetic changes driving the next wave of ovarian cancer trials, from CDK2 and WEE1 inhibitors to PARG inhibitors.
Ponatinib plus blinatumomab may help “a meaningful subset of patients” forego transplant for Ph-positive acute lymphoblastic leukemia.
Ursula A. Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a positive study.
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.
Ursula A. Matulonis, MD, discussed how biomarkers, adverse effects, and patient preference guide choices among recent platinum-resistant ovarian cancer approvals.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acid Reducers, Drug-Drug Interactions, and Setting Expectations for Response
2
How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy
3
Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care
4
How to Work With a Patient Who Declines Cancer Treatment
5